Literature DB >> 22608749

Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer.

Masaki Shiota1, Ario Takeuchi, Akira Yokomizo, Eiji Kashiwagi, Katsunori Tatsugami, Kentaro Kuroiwa, Seiji Naito.   

Abstract

PURPOSE: There are several reports of androgen receptor in bladder cancer cases but androgen receptor expression and the function of androgen/androgen receptor signaling in bladder cancer remain unclear. We investigated androgen receptor expression and the role of androgen/androgen receptor signaling in bladder cancer.
MATERIALS AND METHODS: We evaluated AR mRNA expression in bladder cancer tissue by quantitative real-time polymerase chain reaction. The role of androgen receptor in cell growth and drug sensitivity was also evaluated in vitro and in vivo in several bladder cancer cell lines.
RESULTS: AR mRNA expression inversely correlated with bladder cancer grade, stage and spread. Of several bladder cancer cell lines UMUC3 and MBT-2 markedly expressed androgen receptor transcript and protein. In each cell line androgen/androgen receptor signaling blockade using androgen deprivation, blockade knockdown and antiandrogen agents decreased cell growth, colony formation and cell viability. Androgen receptor expression was implicated in doxorubicin resistance. Inversely androgen receptor deprivation and knockdown made UMUC3 cells sensitive to doxorubicin. Finally, castration slightly suppressed UMUC3 tumor growth in vivo, although this did not attain statistical significance.
CONCLUSIONS: AR transcript expression inversely correlates with bladder cancer clinicopathological characteristics. Androgen/androgen receptor signaling has an important role in the growth and vulnerability to doxorubicin of bladder cancer cells that express androgen receptor. Androgen/androgen receptor signaling might be a possible prophylactic and therapeutic target for bladder cancer that shows androgen receptor expression.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608749     DOI: 10.1016/j.juro.2012.02.2554

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Effects of α1-adrenergic receptor antagonists on the development and progression of urothelial cancer.

Authors:  Yujiro Nagata; Takashi Kawahara; Takuro Goto; Satoshi Inoue; Yuki Teramoto; Guiyang Jiang; Naohiro Fujimoto; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia.

Authors:  H Artee Luchman; Michelle L Villemaire; Tarek A Bismar; Bradley A Carlson; Frank R Jirik
Journal:  Am J Pathol       Date:  2014-01-18       Impact factor: 4.307

Review 3.  Targeted therapies in bladder cancer: an overview of in vivo research.

Authors:  Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2015-09-22       Impact factor: 14.432

Review 4.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

5.  The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer.

Authors:  Marco Moschini; Emanuele Zaffuto; Pierre Karakiewicz; Agostino Mattei; Giorgio Gandaglia; Nicola Fossati; Francesco Montorsi; Alberto Briganti; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-10-01       Impact factor: 4.226

6.  Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells.

Authors:  Chi-Cheng Chen; Teng-Fu Hsieh; Chi-Ping Huang; Ai-Lin Yu; Wen-Lin Chang; Chih-Rong Shyr
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

7.  Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Kenjiro Imada; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Saiji Ohga; Katsumasa Nakamura; Hiroshi Honda; Seiji Naito
Journal:  Oncotarget       Date:  2015-06-10

8.  Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Authors:  Eiji Kashiwagi; Hiroki Ide; Satoshi Inoue; Takashi Kawahara; Yichun Zheng; Leonardo O Reis; Alexander S Baras; Hiroshi Miyamoto
Journal:  Oncotarget       Date:  2016-08-02

Review 9.  Androgen Receptor Signaling in Bladder Cancer.

Authors:  Peng Li; Jinbo Chen; Hiroshi Miyamoto
Journal:  Cancers (Basel)       Date:  2017-02-22       Impact factor: 6.639

Review 10.  Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.

Authors:  Hiroki Ide; Hiroshi Miyamoto
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.